Beyond single-marker analyses: Mining whole genome scans for insights into treatment responses in severe sepsis

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 218-226

  Man, M ^a   Close, S L ^b   Shaw, A D ^c   Bernard, G R ^d   Douglas, I S ^e   Kaner, R J ^f   Payen, D ^g   Vincent, J L ^h   Fossceco, S ^a   Janes, J M ^a   Leishman, A G ^a   O'Brien, L ^a   Williams, M D ^h   Garcia, J G N ⁱ  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

ⁱ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Drotrecogin alfa (activated); epistasis; genetic markers; genome wide association study; polymorphism; severe sepsis

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE 1 RECEPTOR; DROTRECOGIN; PLACEBO;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE RECEPTOR D1 GENE; DOUBLE BLIND PROCEDURE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PECANEX LIKE 2 GENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84878249792     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.1     Document Type: Article

References (49)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al. Sepsis occurrence in acutely Ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-353.
3. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J et al. Surviving sepsis campaign. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38: 367-374.
4. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-618.
5. Bone RC. Important new findings in sepsis. JAMA 1997; 278: 249.
6. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170: 1435-1444.
7. Sriskandan S, Altmann DM. The immunology of sepsis. J Pathol 2008; 214: 211-223.
8. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The pathogenesis of sepsis. Ann Rev Pathol 2011; 6: 19-48.
9. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC et al. PROWESS Sepsis Study Group. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-653.
10. Wang Z, Su F, Rogiers P, Vincent JL. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007; 35: 2594-2600.
11. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
12. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
13. Leone M, Textoris J, Michel F, Wiramus S, Martin C. Emerging drugs in sepsis. Expert Opin Emerg Drugs 2010; 15: 41-52.
14. Anderson R, Schmidt R. Clinical biomarkers in sepsis. Front Biosci (Elite Ed) 2010; 2: 504-520.
15. National Human Genome Research Institute, National Institutes of Health. A catalog of published genome-wide association studies. Available: http://www.genome.gov/2652538 accessed April 2011.
16. Hindorffa LA, Sethupathy P, Junkins HA, Ramosa EM, Mehtac JP, Collins FS et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106: 9362-9367.
17. Groop L, Lyssenko V. Genes and type 2 diabetes mellitus. Curr Diab Rep 2008; 8: 192-197.
18. McPherson R, Pertsemlidis A, Kavaslar, Stewart A, Roberts R, Cox DR et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316: 1488-1491.
19. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392-404.
20. Lobo I. Epistasis: gene interaction and the phenotypic expression of complex diseases like Alzheimer's. Nature Education 2008; 1, Available: http://www.nature.com/scitable/topicpage/Epistasis-Gene-Interaction-and-the- Phenotypic-Expression-90 accessed April 2011.
21. Wu Z, Zhao H. Statistical power of model selection strategies for genome-wide association studies. PLoS Genet 2009; 5: e1000582.
22. Dupuis J, O'Donnell CJ. Interpreting results of large-scale genetic association studies: separating gold from fool's gold. JAMA 2007; 297: 529-531.
23. Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005; 37: 413-417.
24. Evans DM, Marchini J, Morris AP, Cardon LR. Two-stage two-locus models in genomewide association. PLoS Genet 2006; 2: e157.
25. Ionita I, Man M. Optimal two-stage strategy for detecting interacting genes in complex diseases. BMC Genet 2006; 7: 39.
26. Storey JD, Akey JM, Kruglyak L. Multiple locus linkage analysis of genomewide expression in yeast. PLoS Biol 2005; 3: e267.
27. Brem RB, Storey JD, Whittle J, Kruglyak L. Genetic interactions between polymorphisms that affect gene expression in yeast. Nature 2005; 436: 701-703.
28. Zhang Z, Niu A, Sha Q. Identification of interacting genes in genome-wide association studies using a model-based two-stage approach. Ann Hum Genet 2010; 74: 406-415.
29. Lukaszewicz AC, Payen D. The future is predetermined in severe sepsis, so what are the implications? Crit Care Med 2010; 38: S512-S517.
30. The Wellcome Trust Case Control Consortium (WTCCC). Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-678.
31. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-947.
32. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570-584.
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
34. Gabriel SB, Schaffer SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
35. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008; 299: 1335-1344.
36. Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in health and hypertension. Pharmacol Ther 1998; 80: 149-182.
37. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225.
38. Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 2000; 36: 183-186.
39. Staessen JA, Kuznetsova T, Zhang H, Maillard M, Bochud M, Hasenkamp S et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension 2008; 51: 1643-1650.
40. Fung MM, Rana BK, Tang CM, Shiina T, Nievergelt CM, Rao F et al. Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits. Kidney Int 2009; 76: 1070-1080.
41. Svanberg E, Frost RA, Lang CH, Isgaard J, Jefferson LS, Kimball SR et al. IGF-I/IGFBP-3 binary complex modulates sepsis-induced inhibition of protein synthesis in skeletal muscle. Am J Physiol Endocrinol Metab 2000; 279: E1145-E1158.
42. Briard N, Dadoun F, Pommier G, Sauze N, Lebouc Y, Oliver C et al. IGF-I/IGFBPs system response to endotoxin challenge in sheep. J Endocrinol 2000; 164: 361-369.
43. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
44. Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K. The protein C pathway: implications for the design of the RESPOND study. Crit Care 2007; 11: S4.
45. Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM et al. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). J Crit Care 2008; 12: R45.
46. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638-644.
47. Manocha S, Russell JA, Sutherland AM, Wattanathum A, Walley KR. Fibrinogen-beta gene haplotype is associated with mortality in sepsis. J Infect 2007; 54: 572-577.
48. Namath A, Patterson AJ. Genetic polymorphisms in sepsis. Crit Care Clin 2009; 4: 835-856.
49. Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H et al. A single nucleotide polymorphism in NF-{kappa}B inducing kinase is associated with mortality in septic shock. J Immunol 2011; 186: 2321-2328.